Oral BG-12 (Dimethyl Fumarate) significantly reduced multiple sclerosis (MS) relapses and disability progression
21 October 2011 | By Biogen Idec
Phase 3 clinical trial demonstrated significant clinical effects...
List view / Grid view
News
ICON selected by the Biomarkers Consortium of the FNIH
21 October 2011 | By ICON plc
ICON has announced it has received a contract award from the Foundation for the National Institutes of Health (FNIH)...
STELARA® (Ustekinumab) is effective, well-tolerated and improves quality of life in patients with moderate to severe plaque psoriasis inadequately responsive to methotrexate[1,2]
21 October 2011 | By Johnson and Johnson
New data presented at EADV...
AstraZeneca to present new healthcare economics data demonstrating cost-effectiveness of BRILIQUE
21 October 2011 | By AstraZeneca
AstraZeneca will present key results from health economics sub-studies...
Phase II study showed ocrelizumab maintained significant reduction in disease activity for MS patients
20 October 2011 | By Roche
Phase III trials underway to investigate ocrelizumab in two forms of MS...
Abbott to separate into two leading companies
19 October 2011 | By Abbott
Abbott plans to separate into two companies, one in diversified medical products & the other in research-based pharmaceuticals...
Amgen appoints Anthony Hooper Executive Vice President Global Commercial Operations
19 October 2011 | By Amgen
Amgen appoints Anthony Hooper as Executive VP, Global Commercial Operations...
Bristol-Myers Squibb announces changes in senior management team
19 October 2011 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced a series of related changes within its Senior Management Team...
BYETTA® approved for use with insulin glargine in the U.S.
19 October 2011 | By Eli Lilly and Company
FDA has approved a new use for BYETTA® (exenatide) injection....
First results from ongoing Phase III trial show malaria vaccine candidate, RTS,S* reduces the risk of malaria by half in African children aged 5 to 17 months
18 October 2011 | By GlaxoSmithKline
RTS,S* reduces the risk of malaria by half...
AstraZeneca and Forest Laboratories to initiate phase III clinical trials for ceftazidime/avibactam
18 October 2011 | By AstraZeneca
ceftazidime/avibactam (CAZ-AVI) will enter phase III trials...
Novartis drug Gilenya® (fingolimod) shows up to 71% reduction in annualized relapse rates in MS patients
17 October 2011 | By Novartis
Novartis will showcase data from 13 abstracts on fingolimod (Gilenya®)...
Roche signs definitive agreement to acquire Anadys Pharmaceuticals
17 October 2011 | By Roche
Acquisition aims to expand future treatment options for hepatitis C patients...
ICON appoints Colin Stanley President of DOCS
17 October 2011 | By Weber Shandwick
ICON plc, announced the appointment of Colin Stanley as President of DOCS, the company’s global resourcing division...
Positive study of Herceptin given by subcutaneous injection
17 October 2011 | By Roche
Phase III study of a quicker route of administration shows comparable results to intravenous Herceptin...
